Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (FATE)
NASDAQ:FATE
Holding FATE?
Track your performance easily
FATE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.05 - $8.83
Previous Close$2.38
Volume1.17M
Average Volume (3M)1.25M
Market Cap
$252.24M
Enterprise Value$66.71M
Total Cash (Recent Filing)$304.88M
Total Debt (Recent Filing)$100.56M
Price to Earnings (P/E)―
Beta3.22
Next Earnings
Mar 03, 2025EPS Estimate
-$0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding113,877,884
10 Day Avg. Volume1,581,788
30 Day Avg. Volume1,248,570
Standard Deviation0.25
R-Squared0.16
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.68
Price to Sales (P/S)23.67
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.42
Enterprise Value/Gross Profit1.05
Enterprise Value/Ebitda-0.40
Forecast
1Y Price Target
$5.86Price Target Upside164.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Fate Therapeutics News
PremiumCompany Announcements
Fate Therapeutics Unveils Q3 2024 Financial Highlights
PremiumPre-Earnings
Is FATE a Buy, Before Earnings?
PremiumCompany Announcements
Fate Therapeutics Strengthens Legal Safeguards for Leadership
PremiumCompany Announcements
Fate Therapeutics Appoints AI Expert to Enhance Board
Bulls Say, Bears Say
Bulls Say
Clinical TrialsNo dose-limiting toxicities or severe adverse events have been observed in the ongoing Phase I study of FT819 for SLE, and all patients remain on the study.
Financial PerformanceFate ended 2Q24 with roughly $352.0M in cash, which should provide an operational runway to the end of 2026, in our view.
Therapeutic DevelopmentFT825, partnered with Ono, targets HER2 and includes multiple novel edits designed to improve its effectiveness against solid tumors.
Bears Say
Clinical Development RisksRisks include, but are not limited to: unknown clinical efficacy advantage with FT522 relative to other allogeneic and autologous CAR-T approaches.
Pipeline And Market PositionA competitive profile with its iPSC derived programs seems far away, and analysts rate FATE Market Perform as they see limited opportunities for value generation in upcoming months.
Strategic DecisionsThe company announced the decision to halt development of its iPSC-derived CAR-T therapy FT819 in B-cell malignancies and instead pursue further development exclusively in autoimmunity.
---
Ownership Overview
18.52% Insiders
16.12% Mutual Funds
2.47% Other Institutional Investors
49.75% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FATE FAQ
What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was $2.05 and its highest was $8.83 in the past 12 months.
What is Fate Therapeutics’s market cap?
Currently, no data Available
When is Fate Therapeutics’s upcoming earnings report date?
Fate Therapeutics’s upcoming earnings report date is Mar 03, 2025 which is in 109 days.
How were Fate Therapeutics’s earnings last quarter?
Fate Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.416 by $0.016.
Is Fate Therapeutics overvalued?
According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued.
Does Fate Therapeutics pay dividends?
Fate Therapeutics does not currently pay dividends.
What is Fate Therapeutics’s EPS estimate?
Fate Therapeutics’s EPS estimate is -$0.43.
How many shares outstanding does Fate Therapeutics have?
Fate Therapeutics has 113,877,884 shares outstanding.
What happened to Fate Therapeutics’s price movement after its last earnings report?
Fate Therapeutics reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.416. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Fate Therapeutics?
Among the largest hedge funds holding Fate Therapeutics’s share is Deerfield Management Company, LP. It holds Fate Therapeutics’s shares valued at 12M.
---
Fate Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.86 (164.56% Upside)
$5.86 (164.56% Upside)
Blogger Sentiment
Bullish
FATE Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.8%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
15.53%
12-Months-Change
Fundamentals
Return on Equity
-42.10%
Trailing 12-Months
Asset Growth
-9.57%
Trailing 12-Months
Company Description
Fate Therapeutics
Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
---
FATE Earnings Call
Q1 2024
0:00 / 0:00
---
FATE Stock 12 Month Forecast
Average Price Target
$5.86
▲(164.56% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Karyopharm Therapeutics
―
MacroGenics
―
Fulcrum Therapeutics
―
Best Analysts Covering FATE
1 Year
1 Year Success Rate
3/13 ratings generated profit
1 Year Average Return
-12.02%
reiterated a buy rating yesterday
Copying Peter Lawson's trades and holding each position for 1 Year would result in 23.08% of your transactions generating a profit, with an average return of -12.02% per trade.
---